Literature DB >> 31582340

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor.

Sakiyeva Kanshaiym1, Gulmira Zhurabekova1, Ibrahim A Abdelazim2, Tatyana Starchenko1.   

Abstract

Entities:  

Year:  2019        PMID: 31582340      PMCID: PMC7031092          DOI: 10.1016/j.htct.2019.01.008

Source DB:  PubMed          Journal:  Hematol Transfus Cell Ther        ISSN: 2531-1379


× No keyword cloud information.
Dear Respectable Editor, While we are reading with great interest the article published by Friedrisch et al. in the Revista Brasileira de Hematologia e Hemoterapia 2015;37(6):400–5. doi:10.1016/j.bjhh.2015.08.012, many questions came to mind. We would be grateful if the authors clarified the following queries to us and to the readers. First, Friedrisch et al., stated that treatment with intravenous ferric carboxymaltose (FCM) improves indices of anemia, hemoglobin, ferritin and trans-ferrin saturation values. Other authors mentioned that the efficacy of the parenteral iron infusion used for treatment of iron deficiency anemia (IDA), checked by comparing the pre-treatment hemoglobin concentration, serum ferritin, mean corpuscular volume and mean corpuscular hemoglobin with the post-treatment value.2, 3, 4, 5, 6 Second, Friedrisch et al. stated that the intravenous FCM properties permit the administration of large doses (15 mg/kg, maximum of 1000 mg/infusion) in a single and rapid session (15-min infusion), without the requirement of a test dose. Other authors stated that the total parenteral dose for correction of IDA should be given and calculated according to the body weight, hemoglobin deficiency and depleted iron stores, using the following formula: total parenteral iron needed in mg = 2.4 × pre-pregnancy weight in kg × (target hemoglobin − actual hemoglobin) g/dL + 500 mg. Twelve (12) g/dL is the target hemoglobin concentration, 2.4 is the correction factor and 500 mg is the amount of stored iron in pregnant adult women.2, 3, 4, 5, 6, 7, 8 Recently, Froessler et al. applied another regimen of 20 mg/kg body-weight of FCM for treatment of IDA in pregnancy with a maximum dose of 1000 mg in a single infusion and they stated that an ideal dosing regimen currently does not exist.9, 10 Please clarify to us and to the readers the ideal method for checking the efficacy of parenteral iron treatment and the ideal method for the calculation of the total parenteral iron needed for treatment of IDA in pregnancy.

Conclusion

The efficacy of the parenteral iron infusion used for treatment of IDA is checked by comparing the pre-treatment hemoglobin concentration, serum ferritin, MCV and MCH with the post-treatment value. Total parenteral dose for correction of IDA should be given and calculated according to the body weight, hemoglobin deficiency and depleted iron stores, using the following formula: total iron needed in mg = 2.4 × pre-pregnancy weight in kg × (target hemoglobin − actual hemoglobin) g/dL + 500 mg. Twelve (12) g/dL is the target hemoglobin concentration, 2.4 is the correction factor and 500 mg is the amount of stored iron in pregnant adult women. Compliance with ethics guidelines.

Authors’ contributions

SK is responsible for the idea for the letter, intellectual content and update of references. GZ is responsible for the Microsoft editing and update of references. IAA is responsible for the design and submission for publication. TS is responsible for the intellectual content and update of references.

Ethical approval

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflicts of interest

The authors declare no conflicts of interest.
  8 in total

1.  Response to letter to the Editor: Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.

Authors:  Bernd Froessler; Tijana Gajic; Gustaaf Dekker; Nicolette A Hodyl
Journal:  Arch Gynecol Obstet       Date:  2018-10-29       Impact factor: 2.344

2.  Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route.

Authors:  Françoise Bayoumeu; Carole Subiran-Buisset; Nour-Eddine Baka; Henryse Legagneur; Patricia Monnier-Barbarino; Marie Claire Laxenaire
Journal:  Am J Obstet Gynecol       Date:  2002-03       Impact factor: 8.661

3.  Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.

Authors:  Ibrahim A Abdelazim; Bassam Nusair; Shikanova Svetlana; Gulmira Zhurabekova
Journal:  Arch Gynecol Obstet       Date:  2018-10-22       Impact factor: 2.344

Review 4.  Prevalence & consequences of anaemia in pregnancy.

Authors:  K Kalaivani
Journal:  Indian J Med Res       Date:  2009-11       Impact factor: 2.375

5.  Iron deficiency anemia in pregnancy: intravenous versus oral route.

Authors:  Deeba Shafi; Shekhar V Purandare; A V Sathe
Journal:  J Obstet Gynaecol India       Date:  2012-08-01

6.  Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy. A randomized controlled trial.

Authors:  Shruti B Bhavi; Purushottam B Jaju
Journal:  BMC Pregnancy Childbirth       Date:  2017-05-08       Impact factor: 3.007

7.  Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia.

Authors:  João Ricardo Friedrisch; Rodolfo Delfini Cançado
Journal:  Rev Bras Hematol Hemoter       Date:  2015-10-14

8.  Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.

Authors:  Bernd Froessler; Tijana Gajic; Gustaaf Dekker; Nicolette A Hodyl
Journal:  Arch Gynecol Obstet       Date:  2018-05-08       Impact factor: 2.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.